A decade after launching one of the first human-stem-cell-derived skincare collections, FactorFive is expanding its presence in aesthetics with its newest innovation, Exofecta, a topical treatment for post-procedure skin recovery that combines exosomes, growth factors and hyaluronic acid into what the company calls a “biologic trifecta.”
Exofecta is a two-part topical treatment in which practitioners mix freeze-dried exosomes and stem-cell-conditioned growth factors with a hyaluronic acid solution before applying it to the skin following procedures such as microneedling or chemical peels. The treatment has already landed in nearly 400 professional accounts and can cost patients up to $300 per treatment, depending on the provider.
For FactorFive, the launch marks the start of a broader push into the physician and med-spa channel, the brand’s primary growth engine. The professional skincare market is projected to grow roughly 5.5% annually through 2029, according to Technavio.
FactorFive’s direct-to-consumer business remains small by design as the company concentrates its efforts on dermatologists, nurses and aestheticians who use the brand’s serums and post-treatment products in-office. To strengthen its position in the professional channel, FactorFive is positioning itself as both a scientific partner and a business ally to practitioners.
“The overwhelming majority of our business already comes from professionals. So, we asked ourselves, how do we become a better partner to them?” says John Aylworth, co-founder of FactorFive. “When we learned that the average esthetician in California earns about $22 an hour, it reframed our mission. We want products that not only deliver results but help small businesses thrive.”
FactorFive is owned by Xytogen Biotech, a privately held biotechnology firm based in Chico, Calif., that Aylworth started in 2015 with a specialty in human stem cell research. Two years ago, the brand introduced a zero-downtime peel priced to help solo aestheticians and boutique aesthetics practices improve margins. The launch became a blueprint for how FactorFive intends to scale its professional offerings: high-performance formulations built from lab-derived biotech ingredients priced to support profitability for service providers. The brand declined to share revenue or growth targets.
Exofecta is being marketed primarily as a post-procedure add-on employed after treatments such as microneedling, chemical peels or radiofrequency. The positioning taps into a fast-growing segment of professional skincare focused on recovery and barrier repair products designed to extend treatment results and reduce downtime. Brands like Victor Michael, Designs for Health, Plated Skin Science and Biopelle are zeroing in on the segment.
The brands are responding to dermatologists and aesthetic practitioners increasingly looking for products that can both improve outcomes and generate incremental revenue during patient visits. FactorFive’s strategy reflects that shift, creating what Aylworth describes as a bridge between clinical treatments and retail skincare.
“When a client leaves the treatment room with a FactorFive product, the practitioner benefits twice: first from the service, then from the retail sale,” he says. “It’s a way to normalize outcomes and strengthen long-term relationships.”
Exofecta arrives as exosomes flood the skincare market. The tiny extracellular vesicles that facilitate cell-to-cell communication are being promoted as the next frontier in regenerative aesthetics. Dermatology brands, med-spa suppliers and biotech startups alike are exploring exosome-based treatments, although the category remains loosely defined and regulatory oversight is still evolving. Along with FactorFive, brands including Ourself and Epicutis are bringing regenerative medicine concepts—from growth factors to bioactive signaling molecules—to skincare sold through dermatologists and aesthetic clinics as science-backed, biotech-fueled skincare gains momentum.
“Biotech isn’t just about making skin look better. It’s about helping the body heal better.”
Unlike plant-based or synthetic alternatives marketed in some skincare formulas spotlighting exosomes, FactorFive explains its exosomes are derived from human stem-cell-conditioned media produced through what the company calls dynamic cultured media, a proprietary process designed to mimic the body’s natural healing response. The formulation is stabilized through pharmaceutical-grade lyophilization into what it dubs lyo-beads intended to extend shelf life and preserve potency.
Aylworth says, “The more people talk about exosomes without understanding the science, the more it muddies the waters, but it also gives us a platform to explain what’s real.”
With brands rushing into exosomes with formulas of varying quality, Aylworth argues FactorFive’s biotechnology foundation will help it stand apart as the category matures. He asserts FactorFive’s biotechnology model is inherently scalable. “Cells divide exponentially,” says Aylworth. “If we need 10 times more product, we just give them a few more days to grow.”
Behind the scenes, FactorFive is enlarging its product pipeline of professional treatment enhancers, with additional products planned for 2026. International expansion remains limited for now because European Union regulations restrict the use of certain human-origin ingredients in cosmetic formulations.
As biotech continues to blur the line between medicine and beauty, FactorFive sees its role at the intersection of both fields. “Biotech isn’t just about making skin look better,” says Aylworth. “It’s about helping the body heal better, and that has implications far beyond aesthetics.”
